Morgan Ehman

Morgan Ehman

Auto-generated profile, based on publicly available information

Morgan Ehman

Cancer Control Research, BC Cancer Research Institute, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2025 in Genetics in Medicine
Verified
Journal Article
Open access
MEMorgan Ehman
Morgan Ehman
KSKartik Sharma
Kartik Sharma
DWDeirdre Weymann
Deirdre Weymann
TMTatiana Maroilley
Tatiana Maroilley
AMArezoo Mohajeri
Arezoo Mohajeri
DRDean Regier
Dean Regier
Indigenous peoples are underrepresented in reference genome libraries. Consequently, rare disease diagnosis may require bespoke bioinformatics analyses of genome sequences. Establishing diagnostic cost is crucial to support policy development for equitable diagnosis of rare diseases. We estimated the cost and cost trajectory of diagnostic genome sequencing and bioinformatics for Indigenous participants with suspected rare diseases. We conducted a microcosting study of Indigenous children and their families receiving genome sequencing through Canada's Silent Genomes Project. Invoice data informed the costs of genome sequencing. We conducted a time-and-motion study for bioinformatics analyses, including labor, computing, and data storage costs. With standard bioinformatics, costs ranged from C$3645 (SD: 455) for singletons to C$7402 (SD: 566) for trios. With advanced, bespoke bioinformatics, costs ranged from C$5344 (SD: 634) for singletons to C$9760 (SD: 822) for trios. Genome sequencing was a primary cost driver; however, sequencing costs decreased by 61% over 4 years. Bioinformatics costs ranged from 21.3% to 58.3% of the total costs. The time required for bioinformatics ranged from 71 hours to 215 hours for standard and advanced analyses, respectively. Genome sequencing costs decreased over time. Bioinformatics is a significant cost driver, particularly for bespoke analyses arising from nonrepresentative reference libraries.

17 October 2024 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
MEMorgan Ehman
Morgan Ehman
NCNadine Caron
Nadine Caron
LMLaurie Montour
Laurie Montour
DRDean Regier
Dean Regier
Introduction Indigenous peoples and perspectives are under-represented within genomic research. Qualitative methods can help redress this under-representation by informing the development of inclusive genomic resources aligned with Indigenous rights and interests. The difficult history of genomic research with Indigenous peoples requires that research be conducted responsibly and collaboratively. Research guidelines offer structuring principles, yet little guidance exists on how principles translate into practical, community-led methods. We identified the scope and nature of participatory practice described in published qualitative genomic research studies with Indigenous peoples. Methods We performed a search of PubMed, CINAHL, Embase, Scopus and the Bibliography of Indigenous Peoples in North America. Eligible studies reported qualitative methods investigating genomics-related topics with Indigenous populations in Canada, the USA, Australia or New Zealand. Abstracted participatory practices were defined through a literature review and mapped to a published ethical genomic research framework. Results We identified 17 articles. Published articles described a breadth of methods across a diversity of Indigenous peoples and settings. Reported practices frequently promoted Indigenous-partnered research regulation, community engagement and co-creation of research methods. The extent of participatory and community-led practice appeared to decrease as studies progressed. Conclusion Applying non-prescriptive Indigenous genomic research guidelines to qualitative inquiry can be achieved through varied methodological approaches. Our findings affirm the adaptive nature of this process in real-world settings and identify opportunities for participatory practice and improved reporting across the research lifecycle. These findings and the breadth of characterised applied research practices are instructive for researchers seeking to develop much-needed qualitative genomic research partnerships.

1 August 2024 in JCO Precision Oncology
Verified
Journal Article
Open access
SPSamantha Pollard
Samantha Pollard
MEMorgan Ehman
Morgan Ehman
AHAnna Hermansen
Anna Hermansen
DWDeirdre Weymann
Deirdre Weymann
EKEmanuel Krebs
Emanuel Krebs
DRDean Regier
Dean Regier
PURPOSE: In Canada, health data are siloed, slowing bioinnovation and evidence generation for personalized cancer care. Secured data-sharing platforms (SDSPs) can enable data analysis across silos through rapid concatenation across trial and real-world settings and timely researcher access. To motivate patient participation and trust in research, it is critical to ensure that SDSP design and oversight align with patients' values and address their concerns. We sought to qualitatively characterize patient preferences for the design of a pan-Canadian SDSP. METHODS: Between January 2022 and July 2023, we conducted pan-Canadian virtual focus groups with individuals who had a personal history of cancer. Following each focus group, participants were invited to provide feedback on early-phase analysis results via a member-checking survey. Three trained qualitative researchers analyzed data using thematic analysis. RESULTS: Twenty-eight individuals participated across five focus groups. Four focus groups were conducted in English and one in French. Thematic analysis generated two major and five minor themes. Analytic themes spanned personal and population implications of data sharing and willingness to manage perceived risks. Participants were supportive of increasing access to health data for precision oncology research, while voicing concerns about unintended data use, reidentification, and inequitable access to costly therapeutics. To mitigate perceived risks, participants highlighted the value of data access oversight and governance and informational transparency. CONCLUSION: Strategies for secured data sharing should anticipate and mitigate the risks that patients perceive. Participants supported enhancing timely research capability while ensuring safeguards to protect patient autonomy and privacy. Our study informs the development of data-governance and data-sharing frameworks that integrate real-world and trial data, informed by evidence from direct patient input.

24 March 2026 in Genetics in Medicine
Verified
Journal Article
Open access
MEMorgan Ehman
Morgan Ehman
LMLaurie Montour
Laurie Montour
SPSamantha Pollard
Samantha Pollard
DWDeirdre Weymann
Deirdre Weymann
DKDavid Kirk
David Kirk
DRDean Regier
Dean Regier
Genome sequencing (GS) expedites rare disease diagnosis; yet, its benefits remain inequitably distributed. Systemic health care barriers compound genomic underrepresentation to prolong Indigenous children's diagnostic odyssey. We explored Indigenous families' views on accessing and implementing GS as a clinical diagnostic service to inform equitable service design. Together with an Indigenous Advisory Council, we used a talking circle approach to conduct virtual semistructured focus groups with urban-living Indigenous adults in British Columbia, Canada. We performed deductive and inductive thematic analysis to create themes collaboratively with our Indigenous Advisory Council. We returned preliminary interpretations for participants' review and feedback through member checking surveys. Twenty-four individuals participated across 5 focus groups and 1 interview. Participants highlighted resilience as imposed, detrimental, and normalized within health care. They identified a lack of accessible and safe care, the normalization of self-advocacy, and experiences of racism as impeding families' willingness to pursue and benefit from GS. Participants recommended humanizing practices grounded in respectful relations, advocacy support, cultural safety, and Indigenous perspectives on health and wellness. Improving genomic medicine for Indigenous children and families demands more than biomedical advances. Equitable implementation requires collective action to transform health care systems and policies that perpetuate forced resilience.